Professor, Internal Medicine, Ohio State University College of Medicine
Oncology
Dr. Steven M. Devine, MD
|
|
Give Review
Steven Devine is an expert in the field of Oncology. He attended University of Massachusetts Medical School. University of Massachusetts Medical School is ranked 49 in research and 12 in primary care medicine He has 2 awards "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Dr. Steven M. Devine is a published doctor as well. He has 85 publications published. The latest was: Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL... Steven Devine accepts Medicare payments and is listed with Medicare.gov.
Publications
- Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) Acute lymphoblastic leukemia (ALL...
- Endothelial chimerism in Chronic sclerotic-type Chronic Graft-versus-Host disease and GVHD-associated angiomatosis.
- Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen:...
- Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease (GVHD) in Patients Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT).
- Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic...
- Decitabine priming enhances the anti-leukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in Acute myeloid leukemia.
- Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem Cell transplantation: consensus opinion of the Blood and Marrow Transplan...
- Significant improvement in survival after unrelated donor hematopoietic Cell transplantation in the recent era.
- High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS): A 3-Year Interim Report.
- Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma.
- Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant ...
- Lower dose of antithymocyte globulin does not increase Graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem ce...
- Health-related quality of life in patients who develop bronchiolitis obliterans syndrome following allo-SCT.
- A phase 1 study of vorinostat maintenance after autologous transplant in high-risk Lymphoma.
- The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for Lymphoma and multiple myeloma.
- Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with Acute leukaemia and myelodysplasia.
- Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014.
- Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic Cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
- Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis.
- Outcomes after Hematopoietic Stem Cell Transplant for Children with I-Cell Disease.
- Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201.
- An effective mobilization strategy for Lymphoma patients after failed upfront mobilization with plerixafor.
- Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem Cell transplants in patie...
- Peripheral Blood Progenitor Cell Mobilization for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines of the American Society for Blood and Marrow...
- Graft-versus-host disease: why have we not made more progress?
- Genetic Modification of T Cells Redirected towards CS1 Enhances Eradication of Myeloma Cells.
- Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations.
- Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin Lymphoma is associated with prolonged progression-free survival.
- Reprint of: Re-Examining the Role of High-Dose Chemotherapy in the Treatment of Light Chain Amyloidosis.
- Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.
- FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome.
- Chronic myelogenous Leukemia, version 1.2014.
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: ...
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer Cells enhance In Vitro and In Vivo anti-tumor activity against human multiple myeloma.
- Outcomes of hematopoietic SCT recipients with rhinovirus infection: a matched, case-control study.
- Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and Acute B cell malignancies.
- MicroRNAs activate natural killer Cells through toll-like receptor signaling.
- Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell Lymphoma.
- Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease.
- Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
- Early versus delayed autologous stem Cell transplant in patients receiving novel therapies for multiple myeloma.
- Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma.
- Toward a more rational policy for autologous hematopoietic stem Cell mobilization.
- Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for Chronic lymphocytic leukaemia.
- Regulation of Acute graft-versus-host disease by microRNA-155.
- Can we build a better alloGraft?
- Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for Acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials...
- Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study.
- Alternative donor transplantation: results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood Grafts.
- Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic Cell transplantation following fludarabine, busulfan-based re...
- Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell-Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous Leukemia in ...
- CD103 Deficiency Prevents Graft-versus-Host Disease but Spares Graft-versus-Tumor Effects Mediated by Alloreactive CD8 T Cells.
- Dose escalation of lenalidomide in relapsed or refractory Acute leukemias.
- Mantle cell Lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor.
- The PD-1/PD-L1 axis modulates the natural killer Cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.
- Outcome of transplantation for myelofibrosis.
- Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplanta...
- Reduced-intensity conditioning allogeneic stem Cell transplantation in HIV patients with hematologic malignancies: yes, we can.
- Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin Lymphomas.
- Rapid mobilization of functional donor hematopoietic Cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
- Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin Lymphoma.
- Addition of infliximab to standard Acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.
- The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with Acute leukemia undergoing allogeneic transplanta...
- Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of Graft-versus-T cell lymphoma effect.
- A randomized double-blind trial of hydroxychloroquine for the prevention of Chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
- Phase I study of decitabine alone or in combination with valproic acid in Acute myeloid leukemia.
- Human progenitor Cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to Cells from the same donor mobilized by granulocy...
- Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading System.
- Angiogenic Cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100.
- Long-term remissions in patients with myelodysplastic syndrome and secondary Acute myelogenous leukemia undergoing allogeneic transplantation following a reduced inten...
- The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor Cell mobilization is superior to G-CSF alone.
- Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem Cells and hematopoietic stem Cells in hematologic malignancy patients.
- Fatal case of protothecosis in a hematopoietic stem cell transplant recipient after infliximab treatment for Graft-versus-host disease.
- Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's Lymphoma.
- Mesenchymal stem cells distribute to a wide range of tissues following Systemic infusion into nonhuman primates.
- Donor CMV serostatus has no impact on CMV viremia or Disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell trans...
- Recent advances in allogeneic hematopoietic stem-Cell transplantation.
- Reduced duration of cytopenias following melphalan conditioning and autoGrafting for multiple myeloma.
- Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with Myeloid metaplasia.
- Mesenchymal stem Cells: will they have a role in the clinic?
- Improved accuracy of Acute graft-versus-host disease staging among multiple centers.
- Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
- The addition of sirolimus to the Graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre ra...
Schools
University Of Massachusetts Medical School
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
University of Massachusetts Medical School
Hospital
-
Ohio State University Wexner Medical Center
Drug Facts
| NPI NUMBER | 1124036579 | |
| NPPES Provider LastName | DEVINE | |
| NPPES Provider FirstName | STEVEN | |
| NPPES Provider ZIPCode | 432101280 | |
| NPPES Provider State | OH | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 96.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124036579 |
| Last Name Of The Provider | DEVINE |
| First Name Of The Provider | STEVEN |
| View All |
Similar Doctors
|
Dr. Ahmed M. Ghany, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Tarek A. Chidiac, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Yvonne A. Efebera, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kari L. Kendra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kami J. Maddocks-Christianson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Steven K. Clinton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory A. Otterson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erin M. Olson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Thomas E. Olencki, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samantha M. Jaglowski, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rebecca J. Klisovic, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Guido Marcucci, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Maura L. Gillison, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Drew R. Oostra, MD
This Doctor is OpenDoctor Recommended.
|